Base de dados : MEDLINE
Pesquisa : C04.557.386.480.525 [Categoria DeCS]
Referências encontradas : 2531 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 254 ir para página                         

  1 / 2531 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193019
[Au] Autor:Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnený M; SPRINT Trial Investigators
[Ad] Endereço:Department of Molecular Medicine, University of Pavia, Pavia, Italy.
[Ti] Título:Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
[So] Source:Br J Haematol;180(2):224-235, 2018 01.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Linfoma de Célula do Manto/tratamento farmacológico
Linfoma de Célula do Manto/patologia
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Resistência a Medicamentos Antineoplásicos
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Linfoma de Célula do Manto/mortalidade
Masculino
Meia-Idade
Estadiamento de Neoplasias
Modelos de Riscos Proporcionais
Recidiva
Retratamento
Talidomida/administração & dosagem
Talidomida/efeitos adversos
Talidomida/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15025


  2 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776353
[Au] Autor:Wu J; Zhang M; Liu D
[Ad] Endereço:Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
[Ti] Título:Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
[So] Source:Oncotarget;8(4):7201-7207, 2017 Jan 24.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.
[Mh] Termos MeSH primário: Resistência a Medicamentos Antineoplásicos/efeitos dos fármacos
Imidazóis/uso terapêutico
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Linfoma de Célula do Manto/tratamento farmacológico
Pirimidinas/uso terapêutico
Macroglobulinemia de Waldenstrom/tratamento farmacológico
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto
Seres Humanos
Imidazóis/farmacologia
Leucemia Linfocítica Crônica de Células B/genética
Linfoma de Célula do Manto/genética
Mutação
Fosfolipase C gama/genética
Proteínas Tirosina Quinases/antagonistas & inibidores
Proteínas Tirosina Quinases/genética
Pirimidinas/farmacologia
Resultado do Tratamento
Macroglobulinemia de Waldenstrom/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (GS-4059); 0 (Imidazoles); 0 (Pyrimidines); EC 2.7.10.1 (Agammaglobulinaemia tyrosine kinase); EC 2.7.10.1 (Protein-Tyrosine Kinases); EC 3.1.4.3 (Phospholipase C gamma)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.12786


  3 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419676
[Au] Autor:Zheng QF; Li JY; Qin L; Wei HM; Cai LY; Nong B
[Ad] Endereço:Department of Gastroenterology.
[Ti] Título:Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report.
[So] Source:Medicine (Baltimore);97(6):e9799, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Primary gastrointestinal mantle cell lymphoma is rare, and histopathological examination and specific immunohistochemical staining are still the gold standard for diagnosis. Therefore, it is necessary to find a new way to improve positive biopsy rates. PATIENT CONCERNS: A 58-year-old man was admitted to our hospital with epigastric pain, abdominal distension, nausea, and melena. Endoscopy identified submucosal neoplasms and diffuse gastrointestinal tract involvement including the esophagus. DIAGNOSES: A false-negative diagnosis was first determined by ordinary endoscopy. However, a large tissue biopsy was subsequently performed using endoscopic mucosal resection based on endoscopic ultrasonography (EUS). Pathological examination of the biopsy specimens taken from the lesions of the duodenum and rectum revealed diffuse lymphocytic proliferation and obscure nodular and small cleaved cells with irregularly shaped nuclei. Immunohistochemistry showed that the cells were positive for CyclinD1, BCL-2, CD20, CD21, and CD5; however, they were negative for CD3, CD6, CD10, and CD43. INTERVENTIONS: The patient refused to receive further treatment. OUTCOMES: Mantle cell lymphoma was conclusively diagnosed. CONCLUSIONS: EUS has an important role in the diagnosis and management of gastrointestinal submucosal tumors. Performing a pathological biopsy including EUS may be useful for identifying the unknown nature of tumors of the digestive tract.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais
Linfoma de Célula do Manto
[Mh] Termos MeSH secundário: Biópsia/métodos
Ciclina D1/análise
Diagnóstico Diferencial
Duodeno/patologia
Ressecção Endoscópica de Mucosa/métodos
Endossonografia/métodos
Neoplasias Gastrointestinais/diagnóstico
Neoplasias Gastrointestinais/patologia
Neoplasias Gastrointestinais/fisiopatologia
Seres Humanos
Imuno-Histoquímica
Linfoma de Célula do Manto/diagnóstico
Linfoma de Célula do Manto/patologia
Linfoma de Célula do Manto/fisiopatologia
Masculino
Meia-Idade
Reto/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
136601-57-5 (Cyclin D1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009799


  4 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29273915
[Au] Autor:Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
[Ad] Endereço:Department of Pathology and Molecular Medicine, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
[Ti] Título:Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
[So] Source:Ann Hematol;97(3):467-474, 2018 Mar.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chromosomal translocation t(11;14)(q13;q32) is a characteristic molecular marker of mantle cell lymphoma (MCL) and leads to the fusion of the immunoglobulin heavy chain enhancer-promoter with the cyclin D1 gene. Both aberrant cyclin D1 expression and underlying chromosomal aberration may be used as molecular targets for monitoring minimal residual disease (MRD). The present study aims to assess the usefulness of quantitative cyclin D1 gene expression compared to the standardised but more technologically demanding DNA-based method for immunoglobulin heavy chain (IGH) or t(11;14) clone-specific gene rearrangement quantification in a cohort of bone marrow (BM) and peripheral blood (PB) samples from patients with MCL. We simultaneously evaluated DNA-MRD and cyclin D1 expression levels in 234 samples from 57 patients. We observed that both in DNA-MRD positive and negative BM/PB pairs from the same time points the expression levels of cyclin D1 are lower in PB than in BM (median 19×, BM/PB range 0.41-352). The correlation of cyclin D1 transcript levels with DNA-MRD or with flow cytometry was good only in samples with a very high infiltration. In DNA-MRD-negative BM samples, we observed a significant heterogeneity of cyclin D1 expression (in the range of more than three orders of magnitude). This is in contrast to previous reports demonstrating the usefulness of cyclin D1 for MRD monitoring that did not use DNA-based method as a reference. In PB, the specificity of cyclin D1 expression was better due to a lower physiological background. In conclusion, we show that cyclin D1 is unsuitable for MRD monitoring in BM.
[Mh] Termos MeSH primário: Ciclina D1/genética
Linfoma de Célula do Manto/diagnóstico
Linfoma de Célula do Manto/patologia
Monitorização Fisiológica/métodos
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/análise
Biomarcadores Tumorais/genética
Medula Óssea/metabolismo
Medula Óssea/patologia
Ciclina D1/metabolismo
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Linfoma de Célula do Manto/genética
Masculino
Meia-Idade
Neoplasia Residual
RNA Mensageiro/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CCND1 protein, human); 0 (RNA, Messenger); 136601-57-5 (Cyclin D1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171224
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3210-8


  5 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29341562
[Au] Autor:Petkovic I; Stojnev S; Krstic M; Pejcic I; Vrbic S
[Ti] Título:Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?
[So] Source:Vojnosanit Pregl;73(11):1072-5, 2016 Nov.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Synchronous occurrence of lymphomas and other cancers, mostly carcinomas are well established. The most of cases describe chronic lymphocytic leukemia as the leading lymphoproliferative disease with the tendency towards secondary malignancies development. Mantle cell lymphoma (MCL) has been described in only 2 cases to co-occur with prostate adenocarcinoma (PAC). There are scarce data about the connection between MCL and urology cancers. We presented the first case of synchronous occurrence of MCL and PAC in the same patient in Serbia. Case report: A 64-year-old male initially presented with fatigue, splenomegaly, and bicytopenia. The bone marrow biopsy specimen revealed extensive infiltration with MCL. During lymphoma staging procedure prostate enlargement (57 mm) was accidentally found by multislice- computed tomography (MSCT). The serum prostate specific antigen (PSA) was elevated (52 ng/mL; normal values ≤ 4 ng/mL). Transrectal ultrasound biopsy revealed PAC. High Gleason score determined high-risk locally advanced PAC. The patient underwent treatment with chemotherapy and hormone therapy due to the existence of double malignancies. Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) was applied for MCL, and luteinizing hormonereleasing hormone (LHRH) agonist, triptorelin, for PAC. Partial response was obtained for MCL, and stable disease for PAC. In a 1.5-year observation period the patient was still disease progression free for both of malignancies. Conclusion: This case points aut that elderly males are in need for careful observation during the staging procedure for lymphoma. The literature data suggest that MCL patients are in increased risk for urologic malignancies development. However, the etiologic connection between these two entities, except male gender and older age, remains unclear.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Linfoma de Célula do Manto/patologia
Neoplasias Primárias Múltiplas/patologia
Neoplasias da Próstata/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/química
Adenocarcinoma/diagnóstico por imagem
Adenocarcinoma/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Biomarcadores Tumorais/análise
Biópsia
Exame de Medula Óssea
Seres Humanos
Imuno-Histoquímica
Linfoma de Célula do Manto/química
Linfoma de Célula do Manto/tratamento farmacológico
Masculino
Meia-Idade
Tomografia Computadorizada Multidetectores
Gradação de Tumores
Estadiamento de Neoplasias
Neoplasias Primárias Múltiplas/química
Neoplasias Primárias Múltiplas/tratamento farmacológico
Neoplasias da Próstata/química
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/tratamento farmacológico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150425128P


  6 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390561
[Au] Autor:Liu T; Zhang S; Mao H
[Ad] Endereço:Department of Gastroenterology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
[Ti] Título:Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review.
[So] Source:Medicine (Baltimore);96(51):e9410, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Pneumatosis cystoids intestinalis (PCI) is a rare disease in which gas develops in the mucosa or submucosa of the digestive tract. The etiology and pathogenesis of this disease, at present, remain unclear, and gastrointestinal malignant neoplasms may be a potentially important cause. Herein, we report a case of mantle cell lymphoma presenting as PCI as well as present a literature review of cases of suspect PCI that was definitively diagnosed as gastrointestinal neoplasms. In doing so, we highlighted cases of neoplastic pathogenesis that present as PCI. PATIENT CONCERNS: A 55-year-old man was referred to our gastrointestinal department with complaints of intermittent abdominal pain, distention, diarrhea, and occasional melena that persisted for 2 months. He has a history of nasopharyngeal carcinoma. DIAGNOSES: Intensive, translucent, grape-like cystoids of the whole colon and small intestine were disguised as PCI upon colonoscopy and capsule endoscopy. INTERVENTIONS: Right hemicolectomy and ileocecectomy were performed for intussusception and to confirm the diagnosis. Final pathology indicated that the mass was mantle cell lymphoma. OUTCOMES: After surgery and subsequent chemotherapy, the patient showed good recovery and no abnormal lesions were detected on colonoscopy. LESSONS: As shown through this case and a literature review of similar cases of apparent PCI that was definitively diagnosed as gastrointestinal neoplasm, gastrointestinal malignant neoplasms might rarely present as PCI and neoplastic etiologies should also be considered once PCI is detected. Because most patients with malignant PCIs might inevitably experience severe complications, abdominal surgery should be considered and applied timely after unsuccessful resolution by conservative medical therapies and symptomatic treatments.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais/diagnóstico
Linfoma de Célula do Manto/diagnóstico
Pneumatose Cistoide Intestinal/diagnóstico
[Mh] Termos MeSH secundário: Endoscopia por Cápsula
Colonoscopia
Diagnóstico Diferencial
Feminino
Neoplasias Gastrointestinais/patologia
Seres Humanos
Linfoma de Célula do Manto/patologia
Meia-Idade
Pneumatose Cistoide Intestinal/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009410


  7 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461033
[Au] Autor:Agostinelli C; Sabattini E; Pileri SA; Fabbri M
[Ad] Endereço:Haemolymphopathology Unit, Department of Haematology and Oncology "L & A Seragnoli," S. Orsola-Malpighi Hospital, Bologna 40138, Italy. Electronic address: claudio.agostinelli@unibo.it.
[Ti] Título:SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity-reply.
[So] Source:Hum Pathol;66:238-239, 2017 08.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Medula Óssea
Linfoma de Célula do Manto
[Mh] Termos MeSH secundário: Osso e Ossos
Ciclina D1
Seres Humanos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T; COMMENT
[Nm] Nome de substância:
136601-57-5 (Cyclin D1)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  8 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457728
[Au] Autor:Sabour S
[Ad] Endereço:Safety Promotion and Injury Prevention Research Center and Department of Clinical Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran 198353-5511, Islamic Republic of Iran. Electronic address: s.sabour@sbmu.ac.ir.
[Ti] Título:SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity.
[So] Source:Hum Pathol;66:238, 2017 08.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Medula Óssea
Linfoma de Célula do Manto
[Mh] Termos MeSH secundário: Osso e Ossos
Ciclina D1
Seres Humanos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
136601-57-5 (Cyclin D1)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  9 / 2531 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310379
[Au] Autor:Liu J; Wei H; Zhu K; Lai L; Han X; Yang Y
[Ad] Endereço:Department of Pathology, the TongDe Hospital of Zhejiang Province.
[Ti] Título:Male breast cancer and mantle cell lymphoma in a single patient: A case report and literature review.
[So] Source:Medicine (Baltimore);96(48):e8911, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Although still relatively rare, multiple primary malignant neoplasms (MPMNs) have been increasingly reported in recent years. PATIENT CONCERNS AND DIAGNOSES: A 65-year-old man was referred to our hospital for a painless, incidental left axillary lump. Ultrasound showed enlarged left axillary lymph nodes. An excisional biopsy was conducted on 3 lymph nodes. The pathological diagnosis was determined to be metastatic adenocarcinoma and mantle cell lymphoma (MCL) in the lymph nodes. Further physical examination of the patient yielded a 1.5-cm hard, left subareolar mass. INTERVENTIONS AND OUTCOMES: The patient underwent modified radical mastectomy. The diagnosis was grade II invasive ductal carcinoma (stage IIA). The axillary lymph node showed MCL (stage I, group A), but not metastatic ductal carcinoma. The patient received chemotherapy, including 6 courses of CHOP (A chemotherapy protocol consists of cyclophosphamide 1.2 g day 1, doxorubicin 80 mg day 1, vindesine 4 mg day1, and prednisone 90 mg from day 1 to 5) for lymphoma and breast cancer. The patient was also administered endocrine therapy. After a 54-month follow-up, the patient was well with no evidence of disease. LESSONS: MPMNs are easily misdiagnosed as a primary and metastatic tumor, leading to delayed or erroneous treatment. Male breast cancer in a patient with MCL is rare. Early diagnosis and proper therapy are necessary for an optimal prognosis. Further studies are required to define the mechanisms and risk factors of MPMNs.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Neoplasias da Mama Masculina/patologia
Linfoma de Célula do Manto/patologia
Neoplasias Primárias Múltiplas/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/tratamento farmacológico
Adenocarcinoma/cirurgia
Idoso
Biópsia
Neoplasias da Mama Masculina/tratamento farmacológico
Neoplasias da Mama Masculina/cirurgia
Terapia Combinada
Seres Humanos
Linfoma de Célula do Manto/tratamento farmacológico
Linfoma de Célula do Manto/cirurgia
Masculino
Mastectomia
Gradação de Tumores
Neoplasias Primárias Múltiplas/tratamento farmacológico
Neoplasias Primárias Múltiplas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008911


  10 / 2531 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173978
[Au] Autor:Gauthier J; Chantepie S; Bouabdallah K; Jost E; Nguyen S; Gac AC; Damaj G; Duléry R; Michallet M; Delage J; Lewalle P; Morschhauser F; Salles G; Yakoub-Agha I; Cornillon J
[Ad] Endereço:CHRU de Lille, pôle spécialités médicales et gérontologie, service des maladies du sang, secteur allogreffe de cellules souches hématopoïétiques, 59037 Lille, France; Université de Lille, UFR médecine, 59000 Lille, France.
[Ti] Título:[Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
[Ti] Título:Allogreffe de cellules souches hématopoïétiques dans la lymphome de Hodgkin, le lymphome du manteau et autres hémopathies lymphoïdes rares : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)..
[So] Source:Bull Cancer;104(12S):S112-S120, 2017 Dec.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic haematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This manuscript specifically reports on our conclusions regarding Hodgkin's lymphoma as well as rarer entities, such as T cell lymphomas.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas/normas
Doença de Hodgkin/terapia
Linfoma não Hodgkin/terapia
Doenças Raras/terapia
[Mh] Termos MeSH secundário: Aloenxertos
Autoenxertos
França
Seres Humanos
Linfoma de Célula do Manto/terapia
Recidiva
Retratamento/normas
Sociedades Médicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE



página 1 de 254 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde